ASH 2018

American Society of Hematology (ASH) Annual Meeting and Exposition

San Diego, 1–4 December 2018

Breaking news in hematology-oncology

The American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, was held on the 1–4 December.

Explore the news from big trials, updates from key pivotal studies, exciting discoveries in disease biology, as well as the latest CAR T-cell data and MRD insights, and late-breaking abstracts.

View all videos

CLL

Venetoclax and bendamustine plus rituximab or obinutuzumab for CLL

Stephan Stilgenbauer

Ibrutinib emerging as the new standard of care for frontline elderly CLL: ALLIANCE results

Jennifer Woyach

Multiple Myeloma

Quadruplet regimens for newly diagnosed myeloma & MRD-tracking of DKRd-treated patients

Ixazomib prolongs PFS following ASCT in newly diagnosed myeloma

Vincent Rajkumar

Waldenström’s

Association between depth of response and survival in Waldenström’s

Mass spectrometry-flow cytometry study of IgM MGUS progression to Waldenström’s

AML

An update on AMG 330: can BiTEs be as successful in AML as ALL?

Marion Subklewe • 2 Dec 2018

E-selectin antagonist uproleselan for R/R AML: efficacy and safety data

Daniel DeAngelo • 2 Dec 2018

Lymphoma

Updated JULIET results for tisagenlecleucel in DLBCL

Richard Thomas Maziarz • 1 Dec 2018

R2 in the second-line: lenalidomide-rituximab improves PFS in relapsed/refractory NHL

Ian Flinn • 2 Dec 2018

ALL

Initial data for CAR T-cell product JCAR021 in ALL and B-cell lymphoma

Jordan Gauthier • 2 Dec 2018

Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL

Stephan Grupp • 4 Dec 2018

Sickle Cell Disease & β-Thalassemia

BELIEVE: β-thalassemia treatment with luspatercept reduces transfusion burden

Maria Domenica Cappellini

Opioid use in sickle cell is not associated with in-hospital mortality in the US

Oladimeji Akinola Akinboro • 2 Dec 2018

Trial Updates

Updates from MURANO for CLL: time-limited VenR & impact of MRD

Reduced R-CHOP in favourable-prognosis DLBCL doesn’t compromise outlook

Viola Poeschel • 3 Dec 2018

Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse

IciCLLe extension: ibrutinib and obinutuzumab for clears MRD in R/R CLL

CLARITY for CLL: ibrutinib/venetoclax achieve MRD negativity in R/R setting

Novel agent therapies are improving R/R PTCL outcomes

Novel agent therapies are improving R/R PTCL outcomes

Real world ibrutinib efficacy for Waldenström’s macroglobulinemia

Jithma Prasad Abeykoon

Improving the accuracy of Waldenström’s prognosis

Jithma Prasad Abeykoon

CAR-T and ibrutinib in combination: a promising treatment for CLL

Improved outcomes in PTCL with the use of novel agents and transplantation

Improved outcomes in PTCL with the use of novel agents and transplantation

PALB2 predicts poor prognosis in AML and indicates potential targets for synthetic lethal therapies

PALB2 predicts poor prognosis in AML and indicates potential targets for synthetic lethal therapies

Giovanni Martinelli

Successful use of zanubrutinib for R/R MCL in China

Successful use of zanubrutinib for R/R MCL in China

Metabolic profiling of the leukemia stem cell

Metabolic profiling of the leukemia stem cell

Giovanni Martinelli

Ipilimumab, rather than nivolumab for relapsed heme malignancies post allo-SCT

Ipilimumab, rather than nivolumab for relapsed heme malignancies post allo-SCT

Tislelizumab for R/R classical Hodgkin lymphoma

Tislelizumab for R/R classical Hodgkin lymphoma

Venetoclax monotherapy in MCL: longer-term results

Venetoclax monotherapy in MCL: longer-term results

RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML

RADIUS results: midostaurin reduces relapse after ASCT in FLT3-ITD AML

Richard Thomas Maziarz

RB/RC induction for mantle cell lymphoma: promising pooled analysis data

RB/RC induction for mantle cell lymphoma: promising pooled analysis data

1
2
3
4
5
…
15
Next